Intra-Cellular Therapies (NASDAQ:ITCI) Given New $96.00 Price Target at Mizuho

Intra-Cellular Therapies (NASDAQ:ITCI) had its price target boosted by Mizuho from $82.00 to $96.00 in a research report sent to investors on Monday, Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

Several other analysts have also issued reports on ITCI. The Goldman Sachs Group upped their target price on shares of Intra-Cellular Therapies from $67.00 to $77.00 and gave the stock a neutral rating in a research note on Wednesday, April 17th. Needham & Company LLC reiterated a buy rating and issued a $82.00 target price on shares of Intra-Cellular Therapies in a research note on Tuesday, April 16th. Robert W. Baird upped their target price on shares of Intra-Cellular Therapies from $83.00 to $103.00 and gave the stock an outperform rating in a research note on Wednesday, April 17th. TD Cowen upped their target price on shares of Intra-Cellular Therapies from $80.00 to $90.00 and gave the stock a buy rating in a research note on Wednesday, April 17th. Finally, Royal Bank of Canada reiterated an outperform rating and issued a $86.00 target price on shares of Intra-Cellular Therapies in a research note on Wednesday, April 3rd. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of Moderate Buy and a consensus price target of $88.00.

Intra-Cellular Therapies Trading Up 3.0 %

ITCI opened at $74.54 on Monday. The company’s fifty day moving average price is $69.34 and its two-hundred day moving average price is $64.36. Intra-Cellular Therapies has a 1-year low of $45.50 and a 1-year high of $84.89. The company has a market cap of $7.22 billion, a price-to-earnings ratio of -51.05 and a beta of 1.02.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its quarterly earnings data on Thursday, February 22nd. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.14. Intra-Cellular Therapies had a negative net margin of 30.08% and a negative return on equity of 23.02%. The firm had revenue of $132.10 million for the quarter, compared to the consensus estimate of $135.97 million. During the same quarter in the prior year, the company posted ($0.45) earnings per share. The business’s revenue was up 50.3% on a year-over-year basis. As a group, equities analysts forecast that Intra-Cellular Therapies will post -0.67 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Intra-Cellular Therapies news, CEO Sharon Mates sold 20,565 shares of the stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $65.21, for a total transaction of $1,341,043.65. Following the completion of the transaction, the chief executive officer now owns 1,050,309 shares in the company, valued at $68,490,649.89. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Intra-Cellular Therapies news, EVP Michael Halstead sold 7,907 shares of the stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $69.53, for a total transaction of $549,773.71. Following the completion of the transaction, the executive vice president now owns 29,700 shares in the company, valued at $2,065,041. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Sharon Mates sold 20,565 shares of the stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $65.21, for a total transaction of $1,341,043.65. Following the transaction, the chief executive officer now owns 1,050,309 shares of the company’s stock, valued at approximately $68,490,649.89. The disclosure for this sale can be found here. Insiders sold 168,487 shares of company stock worth $11,364,950 over the last quarter. 3.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Intra-Cellular Therapies

A number of institutional investors and hedge funds have recently modified their holdings of the company. Xponance Inc. lifted its holdings in shares of Intra-Cellular Therapies by 3.0% in the fourth quarter. Xponance Inc. now owns 5,676 shares of the biopharmaceutical company’s stock worth $407,000 after buying an additional 163 shares in the last quarter. Regal Investment Advisors LLC lifted its holdings in shares of Intra-Cellular Therapies by 1.4% in the third quarter. Regal Investment Advisors LLC now owns 13,610 shares of the biopharmaceutical company’s stock worth $709,000 after buying an additional 186 shares in the last quarter. State Board of Administration of Florida Retirement System lifted its holdings in shares of Intra-Cellular Therapies by 0.8% in the third quarter. State Board of Administration of Florida Retirement System now owns 26,796 shares of the biopharmaceutical company’s stock worth $1,396,000 after buying an additional 200 shares in the last quarter. Bailard Inc. lifted its holdings in shares of Intra-Cellular Therapies by 1.2% in the fourth quarter. Bailard Inc. now owns 17,080 shares of the biopharmaceutical company’s stock worth $1,223,000 after buying an additional 200 shares in the last quarter. Finally, Global Retirement Partners LLC lifted its holdings in shares of Intra-Cellular Therapies by 13.8% in the third quarter. Global Retirement Partners LLC now owns 1,753 shares of the biopharmaceutical company’s stock worth $89,000 after buying an additional 213 shares in the last quarter. 92.33% of the stock is owned by hedge funds and other institutional investors.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.